Search clinical trials for: Placebo Almonertinib

Total 53913 results

Sun Yat-sen University

Not yet recruiting

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (AERESA)

Lung Cancer

China
Hansoh BioMedical R&D Company

Not yet recruiting

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Poor Performance Status | Malignant Tumor of Lung

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial (AUTUMN)

Non Small Cell Lung Cancer

China
Shanghai Cancer Hospital, China

Recruiting

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. (APPROACH)

Lung Cancer

China
Yuan Chen

Recruiting

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

NSCLC, Stage III

China
Sun Yat-sen University

Enrolling by invitation

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Safety of Almonertinib

China
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Brain Metastases | Radiotherapy | EGFR Activating Mutation

China
Zhejiang Cancer Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases (ACHIEVE)

Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Metastatic Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance (APPEAR)

Safety

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Non Small Cell Lung Cancer | EGFR Activating Mutation | Stage III NSCLC

China
First People's Hospital of Hangzhou

Not yet recruiting

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Brain Metastases | EGFR Positive Non-small Cell Lung Cancer

China
Li-kun Chen

Recruiting

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Lung Cancer

China
Merck Sharp & Dohme LLC

Completed

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

Respiratory Syncytial Virus

United Kingdom
Shanghai Chest Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE)

Lung Cancer | EGFR Gene Mutation
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
EQRx, Inc.

Completed

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

NSCLC | Healthy Volunteers | Pharmacokinetics

United States, New Zealand
Qianfoshan Hospital
Shandong Provincial Hospital

Not yet recruiting

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer (MWA)

Advanced Non Small Cell Lung Cancer

China
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Laibin People's Hospital

Not yet recruiting

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Lung Cancer Stage III
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Kunming Medical University

Recruiting

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

China
Henan Cancer Hospital

Recruiting

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

NSCLC | Brain Metastases | Leptomeningeal Metastasis

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC (ACROSS1)

Non Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation (ACROSS2)

Non Small Cell Lung Cancer

China
Marinus Pharmaceuticals

Completed

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

PCDH19-Related Epilepsy

United States, Hungary, Italy, Netherlands, Poland
Chongqing University Cancer Hospital

Recruiting

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Non-Small Cell Lung Cancer (NSCLC)

China
Shanghai Chest Hospital

Not yet recruiting

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (ATTACK)

NSCLC
Fujian Cancer Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma (ARISE)

Pulmonary Adenosquamous Carcinoma

China
Second Affiliated Hospital of Nanchang University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (ATTRACT)

NSCLC | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.; GeneCast Biotechnology Co., Ltd.

Enrolling by invitation

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection (APEX)

Non-small Cell Lung Carcinoma

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (NEOVADE)

Non Small Cell Lung Cancer | EGFR Gene Mutation

China
Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
Tianjin Medical University Cancer Institute and...

Unknown

Almonertinib With Chemotherapy in mEGFR NSCLC

Non-Small Cell Lung Cancer Metastatic

China
Fudan University

Unknown

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer (APPEAL)

Lung Cancer, Non-small Cell | EGFR Gene Mutation | EGFR T790M

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Advanced Malignancies

China

3

Subscribe